

PATENT  
Docket No.:LAY-006CLA

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1632

Examiner: Anne Marie Baker

Serial No. 09/494,088

Filed: 01/28/2000

In re Application of: McGrogan

DRAFT

For: Production and Use of Dopaminergic Cells to Treat Dopaminergic Deficiencies

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail, in an envelope addressed to Director of Patents, Box \_\_\_\_\_ Washington, D.C. 20231 on \_\_\_\_\_, Signed \_\_\_\_\_

RESPONSE TO OFFICE ACTION  
DRAFT AMENDMENTDirector of Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated January 3, 2002, Applicant(s) respectfully respond. The amendments here presented are made for the purposes of better defining the invention, rather than to overcome the rejections for patentability. No presumption should therefore attach that the claims have been narrowed over those earlier presented, or that subject matter or equivalents thereof to which the Applicants are entitled has been surrendered. No new matter has been introduced by these amendments. Reconsideration and allowance is respectfully requested in view of the amendments and the following remarks.

## In the Claims:

1. (amended) A method of producing dopaminergic neuronal cells [suitable for transplantation in dopamine deficiencies], said [transplantable] neuronal cells being derived from progenitor cells,
  - a. providing progenitor cells which lack at least one indicator of neuronal cell differentiation;
  - b. treating the progenitor cells with an inducing agent for a time period sufficient to optimize expression of tyrosine hydroxylase and to induce the presence of at least one indicator of neuronal cell differentiation to produce a plurality of dopaminergic, differentiated neuronal cells; and